Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: A placebo-controlled, double-blind, multicentre study

Diabetic Medicine

Volumn 16, Issue 3, 1999, Pages 228-232

  Riccardi, Gabriele ^c   Giacco, R ^d   Parillo, M ^d   Turco, S ^d   Rivellese, A A ^d   Ventura, M R ^d   Contadini, S ^d   Marra, G ^d   Monteduro, M ^d   Santeusanio, F ^d   Brunetti, P ^d   Librenti, M C ^a   Pontiroli, A E ^a   Vedani, P ^a   Pozza, G ^a   Bergamini, L ^b   Bianchi, C ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Medical Department   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NONE

Author keywords

Acarbose; Efficacy; Safety; Type 1 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; CARBOHYDRATE INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY FIBER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIETARY CARBOHYDRATES; DIETARY FIBER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRISACCHARIDES;

EID: 0032709937     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00047.x     Document Type: Article

References (20)

1. 1 Truscheit E, Hillebrand I, Junge B, Müller L, Puls W, Schmidt D. Microbial alpha-glucosidase inhibitors: chemistry, biochemistry and therapeutic potential. Prog Clin Biochem Med 1988; 7: 17-99.
2. 2 Hillebrand I, Boehme K, Frank G, Fink H, Berchthold P. The effects of the alpha-glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin and triglyceride levels in man. Res Exp Med 1979; 175: 81-86.
3. 3 Puls W, Bischoff H, Schutt H. Pharmacology of amylase- and glucosidase-inhibitors. In: Creutzfeldt W, Fölsch UR, eds. Delaying Absorption as a Therapeutic Principle in Metabolic Diseases. Stuttgart: Thieme-Verlag, 1983: 70-76.
4. 4 Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994; 17: 561-566.
5. 5 Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928-935.
6. 6 Rodgez NW, Chiasson J-L, Hunt JA, Josse RG, Palmeson C, Ross SA et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clin Invest Med 1995; 4: 318-324.
7. 7 Lam KSL, Tiu SC, Tsang MW, IpTP, Tam SCF. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care 1998; 21: 1154-1158.
8. 8 Johnston PS, Feig P, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of african-american type 2 diabetic patients with a-glucosidase inhibition. Diabetes Care 1998; 21: 416-422.
9. 9 Johnston PS, Feig P, Coniff RF, Krol A, Haffner SM. Long-term titrated-dose a-glucosidase Inhibition in non-insulin-requiring hispanic NIDDM patients. Diabetes Care 1998; 21: 409-415.
10. 10 Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new a-glucosidase Inhibitor (BAY m1099-Miglitol) in insulin-treated type 2 diabetes mellitus. Diabetic Med 1998; 15: 657-660.
11. 11 Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of Type 1 diabetes. Diabetes Care 1997; 20: 248-253.
12. 12 Dimitriadis G, Karaiskos C, Raptis S. Effect of prolonged (6 months) alpha-glucosidase on blood glucose control and insulin requirwment in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986; 18:253-255.
13. 13 World Health Organization. Diabetes mellitus: report of a WHO Study Group. Technical Report No 727. Geneva: World Health Organization, 1985.
14. 14 American Diabetes Association. Clinical Practice recommendations. Diabetes Care 1997; 20: S14-S17.
15. 15 Diabetes and Nutrition Study Group of European Association for the Study of Diabetes (EASD). Recommendation for the nutritional managment of patients with diabetes mellitus. Diabetes, Nutrition and Metabolism 1995; 8: 1-4.
16. 16 Rivellese AA, Ventura MR, Vespasiani G, Bruni M, Moriconi V, Pacioni D et al. Evaluation of a new computerized method for the Seven Day Food Record in insulin dependent diabetic patients. Diabetes Care 1991; 14: 602-604.
17. 17 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-86.
18. 18 Taylor RH. Post-prandial hyperglycaemia and diabetic complications. Practical Diabetes 1993; 10: S10-S14.
19. 19 Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetic Medicine 1998; 15: 188-193.
20. 20 Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-473.